CTKB
Cytek Biosciences, Inc.
Next earnings Aug 4, 2026 (after close) · consensus $-0.09 EPS, $49.6M rev
Last earnings -0.4% on 2026-05-07
$4.28
▲ +5.16%$4.28▲ +39.41%
over 1Y
L $2.95EODHDH $5.88
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.2%
1W+7.5%
1M+7.8%
3M-7.0%
YTD-13.0%
1Y+39.4%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Conservative balance sheet (liabilities/equity 0.35x); but unprofitable (net margin -33.0%).
Cytek Biosciences, Inc. shows $201M in FY2025 revenue (+0.5% YoY), a -33.0% net margin, and -19.5% ROE.
Sources: SEC EDGAR (CIK 0001831915, latest 10-Q filed 2026-05-07) · EODHD · as of 6/25/2026, 7:08:40 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.